Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac for the season 2008/2009. An open-label, baseline-controlled multi-center study in two groups: Adult subjects and elderly subjects.

Trial Profile

Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac for the season 2008/2009. An open-label, baseline-controlled multi-center study in two groups: Adult subjects and elderly subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 15 Mar 2012 Actual initiation date changde from Jun 2008 to 25 may 2008 as reported by European Clinical Trials Database.
    • 15 Mar 2012 Planned end date changed from 1 Jul 2008 to 25 May 2009 as reported by European Clinical Trials Database.
    • 12 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top